Ozempic was supposed to fix the obesity crisis. Now we’re finding out it might be quietly dismantling the one thing that keeps your body running long-term: physical activity. This isn’t a side effect doctors are shouting about. It should be.
A new study covered by Science Daily found that people taking GLP-1 receptor agonists like semaglutide — the active ingredient in Ozempic and Wegovy — started moving significantly less over time. Not a little less. Measurably, trackably less. The drugs that are being prescribed to millions of people as a path toward healthier bodies appear to be making those bodies more sedentary. That’s a problem with a capital P.
What GLP-1 Drugs Actually Do
Let’s back up. GLP-1 stands for glucagon-like peptide-1. It’s a hormone your gut releases after you eat. It tells your pancreas to pump insulin, tells your stomach to slow down, and — critically — tells your brain you’re full. Semaglutide mimics that hormone artificially. Inject it once a week and suddenly your appetite collapses. You eat less. You lose weight. The numbers on the scale move in the right direction.
That’s the pitch. And for pure weight loss, it works. Trials have shown people losing 15 to 20 percent of their body weight over a year. That’s not nothing. For people with obesity-related conditions like Type 2 diabetes, heart disease risk, or sleep apnea, that kind of loss can genuinely change outcomes.
But weight loss and health are not the same thing. They overlap. They are not identical.
The Movement Problem Nobody Wants To Talk About
Here’s what the research is showing: when people take these drugs and eat less, they also start doing less. Their total energy expenditure drops. Part of that is expected — smaller bodies burn fewer calories. But the activity reduction goes beyond simple physics. People on GLP-1 drugs appear to be spontaneously moving less throughout their day. Fewer steps. Less fidgeting. Less of what scientists call non-exercise activity thermogenesis, or NEAT.
NEAT is the unsung hero of metabolic health. It’s not your gym session. It’s everything else — walking to your car, standing in the kitchen, pacing during a phone call. It accounts for a huge chunk of daily calorie burn for most people. When it drops, your metabolism slows in ways that compound over time.
The theory is that the brain regions GLP-1 drugs target — the ones that suppress appetite — may also be suppressing the drive to move. Your body, sensing reduced fuel coming in, starts conserving energy across the board. It’s smart biology. It is also a metabolic trap.
Muscle Loss Makes It Worse
Rapid weight loss without resistance training almost always comes with muscle loss. Muscle is metabolically expensive tissue. Your body will sacrifice it when calories are scarce. And if you’re simultaneously moving less, you’re giving your body every reason to shed it fast.
Muscle loss in the context of GLP-1 drugs has been a concern since these medications went mainstream. Some researchers estimate that up to 40 percent of weight lost on semaglutide can come from lean mass. Move less, eat less, lose muscle — and your metabolic rate tanks. Stop the drug, regain the weight, but not the muscle. You end up in a worse metabolic position than where you started.
This isn’t hypothetical doom-scrolling. It’s basic exercise physiology playing out at population scale.
The Hot Take
Ozempic is the tech industry of medicine. Everyone’s obsessed with the short-term output — the weight dropping, the before-and-after photos, the stock prices — and nobody wants to audit the downstream costs until it’s too late. We handed millions of people a powerful metabolic intervention with almost zero structured support around exercise, muscle maintenance, or behavioral change. We just gave them the drug and called it a solution. That’s not healthcare. That’s a subscription model with a nasty cancellation fee.
What Should Actually Happen Now
Prescribing GLP-1 drugs without mandatory, structured physical activity guidance is like handing someone a one percent shot at winning the World Cup and not giving them a coach. Technically possible. Practically doomed.
Doctors need to be having explicit conversations with patients about resistance training before the first injection. Not as an optional bonus. As a non-negotiable part of the protocol. The drugs lower the drive to move. You have to consciously fight that. You have to build the habit before the drug takes that impulse away.
Insurance companies covering semaglutide should be covering supervised exercise programs too. The data will eventually force that conversation. Better to get ahead of it.
And patients deserve honesty. Not fear-mongering — the drugs do real good for real people. But the framing of “take this shot and lose weight” without the asterisk of “and you need to actively resist the urge to become sedentary” is incomplete medicine. While you’re rethinking what you’re passively consuming — your feeds, your platforms, your defaults — whether that’s social media or pharmaceuticals — the question worth asking is always the same: what’s the real cost, and who told you about it upfront?
GLP-1 drugs are powerful tools. Tools used wrong still cause damage. The science is telling us something. Time to listen before the bill comes due at scale.